Last reviewed · How we verify
Vaginal tablet Endometrin twice a day — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Vaginal tablet Endometrin twice a day (Vaginal tablet Endometrin twice a day) — Wolfson Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vaginal tablet Endometrin twice a day TARGET | Vaginal tablet Endometrin twice a day | Wolfson Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vaginal tablet Endometrin twice a day CI watch — RSS
- Vaginal tablet Endometrin twice a day CI watch — Atom
- Vaginal tablet Endometrin twice a day CI watch — JSON
- Vaginal tablet Endometrin twice a day alone — RSS
Cite this brief
Drug Landscape (2026). Vaginal tablet Endometrin twice a day — Competitive Intelligence Brief. https://druglandscape.com/ci/vaginal-tablet-endometrin-twice-a-day. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab